Neurocrine Biosciences Inc
NASDAQ:NBIX
Neurocrine Biosciences Inc
Neurocrine Biosciences Inc. is a biopharmaceutical company that has carved out a notable niche in the neurosciences landscape. Founded in 1992, this San Diego-based firm has dedicated itself to developing treatments for neurological and endocrine-related disorders. With a strong focus on conditions such as Parkinson's disease, tardive dyskinesia, and epilepsy, Neurocrine leverages its expertise in neuroscience to bring innovative therapies to those who need them most. The company’s flagship product, Ingrezza, primarily used to treat tardive dyskinesia, reflects their commitment to addressing complex, unmet medical needs. Successfully obtaining FDA approval not only boosted patient outcomes but also established Neurocrine as a leader in a specialized segment of the pharmaceutical industry.
Neurocrine’s financial model thrives on the commercialization of its proprietary medications. By partnering strategically with other pharmaceutical giants, such as AbbVie, they can broaden their market reach and accelerate development of new treatments. The company generates revenue predominantly through product sales, royalties, and milestone payments associated with its collaborations. Their pipeline remains robust, focusing on both expanding indications for existing drugs and pioneering new treatments. Each new approval or advancement in clinical trials further solidifies their market position and offers potential for increased financial returns. Thus, Neurocrine Biosciences operates at the intersection of science and business, continuously pushing the boundaries of neurological treatment while maintaining a steady growth trajectory.
Neurocrine Biosciences Inc. is a biopharmaceutical company that has carved out a notable niche in the neurosciences landscape. Founded in 1992, this San Diego-based firm has dedicated itself to developing treatments for neurological and endocrine-related disorders. With a strong focus on conditions such as Parkinson's disease, tardive dyskinesia, and epilepsy, Neurocrine leverages its expertise in neuroscience to bring innovative therapies to those who need them most. The company’s flagship product, Ingrezza, primarily used to treat tardive dyskinesia, reflects their commitment to addressing complex, unmet medical needs. Successfully obtaining FDA approval not only boosted patient outcomes but also established Neurocrine as a leader in a specialized segment of the pharmaceutical industry.
Neurocrine’s financial model thrives on the commercialization of its proprietary medications. By partnering strategically with other pharmaceutical giants, such as AbbVie, they can broaden their market reach and accelerate development of new treatments. The company generates revenue predominantly through product sales, royalties, and milestone payments associated with its collaborations. Their pipeline remains robust, focusing on both expanding indications for existing drugs and pioneering new treatments. Each new approval or advancement in clinical trials further solidifies their market position and offers potential for increased financial returns. Thus, Neurocrine Biosciences operates at the intersection of science and business, continuously pushing the boundaries of neurological treatment while maintaining a steady growth trajectory.
Record Sales: Neurocrine reported $790 million in net product sales for Q3 2025, up 28% year-over-year, led by INGREZZA and strong early adoption of CRENESSITY.
CRENESSITY Launch: CRENESSITY achieved $98 million in Q3 sales, up from $53 million in Q2, with high patient persistence and reimbursement rates.
INGREZZA Momentum: INGREZZA saw $687 million in Q3 net sales, with three consecutive quarters of record new patient starts and expanding prescriber base.
Sales Force Expansion: Both INGREZZA and CRENESSITY sales teams will be expanded by roughly 30% to support continued growth, with $150 million added to SG&A in 2026.
Pipeline Progress: Late-stage clinical programs are enrolling well, with expectations to meet Phase I and II study initiation goals; key readouts are anticipated in Q4.
IRA/Market Access: Management is focused on maximizing patient share ahead of IRA impacts; current formulary coverage for INGREZZA expected to remain stable through 2026.
Financial Strength: Neurocrine ended the quarter with over $2.1 billion in cash and reiterated its capital allocation priorities.
